Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in c-Kit Mutated Metastatic Melanoma
NCT02501551Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Feb 2015
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in melanoma, sponsored by Yonsei University. Primary endpoint: Disease Control Rate at 8 weeks. Status: unknown.
02
Drugs
regorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02501551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501551.